Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins.
Heat-shock protein 90 (Hsp90) inhibitors exhibit activity against human cancers. We evaluated a series of new, oral bioavailable, chemically diverse Hsp90 inhibitors (PU-H71, AUY922, BIIB021, NVP-BEP800) against Kaposi sarcoma (KS). All Hsp90 inhibitors exhibited nanomolar EC(50) in culture and AUY9...
Guardado en:
Autores principales: | Wuguo Chen, Sang-Hoon Sin, Kwun Wah Wen, Blossom Damania, Dirk P Dittmer |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ec99fa99ca52432982fd1ce381d2e336 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Viral Profiling Identifies Multiple Subtypes of Kaposi’s Sarcoma
por: Mina C. Hosseinipour, et al.
Publicado: (2014) -
Viral and immunological markers of HIV-associated Kaposi sarcoma recurrence.
por: Owen Ngalamika, et al.
Publicado: (2021) -
Kaposi’s Sarcoma in Virally Suppressed People Living with HIV: An Emerging Condition
por: Romain Palich, et al.
Publicado: (2021) -
EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing’s Sarcoma and Chondrosarcoma
por: Giorgia Giordano, et al.
Publicado: (2021) -
Viral oncogene-induced DNA damage response is activated in Kaposi sarcoma tumorigenesis.
por: Sonja Koopal, et al.
Publicado: (2007)